scholarly journals Impaired T helper cell responses in human immunodeficiency virus‐exposed uninfected newborns

2021 ◽  
Author(s):  
Yesenia Brito‐Pérez ◽  
Rodrigo T. Camacho‐Pacheco ◽  
Noemi Plazola‐Camacho ◽  
Diana Soriano‐Becerril ◽  
Irma A. Coronado‐Zarco ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
T Helper Cell ◽  
Helper Cell ◽  
T Helper ◽  
Cell Responses ◽  
Immunodeficiency Virus ◽  
Exposed Uninfected

Reconstitution of Long-Term T Helper Cell Function after Zidovudine Therapy in Human Immunodeficiency Virus-Infected Patients

1992 ◽  
Vol 166 (4) ◽  
pp. 723-730 ◽  
Author(s):  
Mario Clerici ◽  
Alan L. Landay ◽  
Harold A. Kessler ◽  
John P. Phair ◽  
David J. Venzon ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cell Function ◽  
T Helper Cell ◽  
Zidovudine Therapy ◽  
Helper Cell ◽  
T Helper ◽  
Immunodeficiency Virus

scholarly journals Changes in T-helper cell function in human immunodeficiency virus- infected children during didanosine therapy as a measure of antiretroviral activity

Blood ◽  
1992 ◽  
Vol 80 (9) ◽  
pp. 2196-2202 ◽  
Author(s):  
M Clerici ◽  
E Roilides ◽  
KM Butler ◽  
L DePalma ◽  
D Venzon ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Bacterial Infections ◽  
Cell Function ◽  
Interleukin 2 ◽  
T Helper Cell ◽  
Helper Cell ◽  
T Helper ◽  
Asymptomatic Patients ◽  
Immunodeficiency Virus ◽  
P24 Antigen

Abstract Didanosine has shown activity against the human immunodeficiency virus (HIV) in both children and adults. We prospectively assessed T-helper cell (Th) function as determined by in vitro interleukin-2 (IL-2) production in response to a panel of T-cell stimuli in 22 HIV-infected children before and during didanosine therapy and we correlated the incidence of opportunistic and recurrent bacterial infections with changes in p24 antigen and CD4 counts. Didanosine (270, 360, or 540 mg/m2/d) was administered orally for periods ranging from 8 to 40 weeks (mean, 24 weeks). Five of six asymptomatic patients (Centers for Disease Control P-1) compared with 6 of 16 symptomatic (P-2) patients exhibited improved Th function (greater than threefold increase in IL-2 production to at least 2 of the 4 stimuli) during therapy. Of 12 patients without infections during therapy, 9 (75%) showed improvement in Th function, compared with only 2 of 10 patients with infections (P = .03). Notably, the incidence of infections was not correlated with improvements in CD4 count or decreases in p24 antigen. Improvement in Th function during didanosine therapy is correlated with decreased incidence of infections. Assessment of Th function may provide an additional measurement of immunologic response to antiretroviral therapy.

scholarly journals Changes in T-helper cell function in human immunodeficiency virus- infected children during didanosine therapy as a measure of antiretroviral activity

Blood ◽  
1992 ◽  
Vol 80 (9) ◽  
pp. 2196-2202
Author(s):  
M Clerici ◽  
E Roilides ◽  
KM Butler ◽  
L DePalma ◽  
D Venzon ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Bacterial Infections ◽  
Cell Function ◽  
Interleukin 2 ◽  
T Helper Cell ◽  
Helper Cell ◽  
T Helper ◽  
Asymptomatic Patients ◽  
Immunodeficiency Virus ◽  
P24 Antigen

Didanosine has shown activity against the human immunodeficiency virus (HIV) in both children and adults. We prospectively assessed T-helper cell (Th) function as determined by in vitro interleukin-2 (IL-2) production in response to a panel of T-cell stimuli in 22 HIV-infected children before and during didanosine therapy and we correlated the incidence of opportunistic and recurrent bacterial infections with changes in p24 antigen and CD4 counts. Didanosine (270, 360, or 540 mg/m2/d) was administered orally for periods ranging from 8 to 40 weeks (mean, 24 weeks). Five of six asymptomatic patients (Centers for Disease Control P-1) compared with 6 of 16 symptomatic (P-2) patients exhibited improved Th function (greater than threefold increase in IL-2 production to at least 2 of the 4 stimuli) during therapy. Of 12 patients without infections during therapy, 9 (75%) showed improvement in Th function, compared with only 2 of 10 patients with infections (P = .03). Notably, the incidence of infections was not correlated with improvements in CD4 count or decreases in p24 antigen. Improvement in Th function during didanosine therapy is correlated with decreased incidence of infections. Assessment of Th function may provide an additional measurement of immunologic response to antiretroviral therapy.

T helper cell epitopes of the human immunodeficiency virus (HIV-1) nef protein in rats and chimpanzees

1992 ◽  
Vol 29 (4) ◽  
pp. 489-499 ◽  
Author(s):  
Jerome Estaquier ◽  
Christophe Boutillon ◽  
Jean-Claude Ameisen ◽  
Helene Gras-Masse ◽  
Jean-Pierre Lecocq ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
T Helper Cell ◽  
Helper Cell ◽  
T Helper ◽  
Immunodeficiency Virus ◽  
Hiv 1

scholarly journals Limited Breadth of a T-Helper Cell Response to a Human Immunodeficiency Virus Envelope Protein

2003 ◽  
Vol 77 (7) ◽  
pp. 4231-4236 ◽  
Author(s):  
X. Zhan ◽  
K. S. Slobod ◽  
S. Surman ◽  
S. A. Brown ◽  
T. D. Lockey ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cell Response ◽  
Envelope Protein ◽  
T Helper Cell ◽  
Helper Cell ◽  
T Helper ◽  
Virus Envelope ◽  
Immunodeficiency Virus ◽  
Natural Variant ◽  
Virus Envelope Protein

ABSTRACT Single-envelope human immunodeficiency virus (HIV) vaccines have been studied for more than a decade, with some successes in homologous challenge experiments in nonhuman primates but with no clear successes in clinical trials. To gain insight into the breadth of the immunity elicited by such vaccines, we have dissected the T-helper cell response of C57BL/6 mice to an individual, molecularly cloned envelope protein. Here, we report that T-helper cells responsive to HIV type 1 1035 envelope are very highly restricted in C57BL/6 animals: seven different hybridomas recovered from five separate mice recognized the same peptide, PKVSFEPIPIHYCAP, located in the C2 region of gp120. Three of these hybridomas were tested on a natural variant of the peptide but failed to respond. A more extensive analysis of whole splenic populations from other C57BL/6 mice immunized with the 1035 envelope reproducibly confirmed that the gp120-specific T-helper response was almost exclusively focused on a single epitope. We conclude that single-envelope vaccines may frequently fail to provoke an immune response sufficiently diverse to recognize variant sequences among circulating HIV. The results encourage the inclusion of more than one envelope in future vaccines to enhance the potential diversity and respective surveillance capacities of responding T-helper cell populations.

Sign in / Sign up

Export Citation Format

Share Document